GSK (NYSE:GSK) Raised to “Strong-Buy” at StockNews.com

GSK (NYSE:GSK) was upgraded by stock analysts at StockNews.com from a “buy” rating to a “strong-buy” rating in a report issued on Thursday.

GSK has been the topic of a number of other research reports. Barclays raised GSK to a “hold” rating in a report on Tuesday, August 27th. Guggenheim downgraded shares of GSK from a “buy” rating to a “neutral” rating in a report on Thursday, October 31st. Deutsche Bank Aktiengesellschaft cut shares of GSK from a “buy” rating to a “hold” rating in a research note on Friday, November 15th. Finally, Jefferies Financial Group lowered shares of GSK from a “buy” rating to a “hold” rating and decreased their target price for the stock from $53.00 to $39.50 in a report on Tuesday, November 12th. Seven analysts have rated the stock with a hold rating and four have assigned a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $43.25.

GSK Trading Down 0.7 %

Shares of GSK stock opened at $33.95 on Thursday. GSK has a 1 year low of $32.83 and a 1 year high of $45.92. The company’s fifty day simple moving average is $36.28 and its two-hundred day simple moving average is $39.36. The company has a debt-to-equity ratio of 0.98, a current ratio of 0.81 and a quick ratio of 0.53. The stock has a market capitalization of $70.35 billion, a price-to-earnings ratio of 22.19, a PEG ratio of 1.54 and a beta of 0.64.

Insider Activity at GSK

In other GSK news, major shareholder Plc Gsk acquired 2,791,930 shares of the company’s stock in a transaction on Friday, September 27th. The stock was acquired at an average price of $8.00 per share, for a total transaction of $22,335,440.00. Following the acquisition, the insider now owns 16,775,691 shares in the company, valued at $134,205,528. This represents a 19.97 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. 10.00% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On GSK

A number of institutional investors have recently bought and sold shares of GSK. Sunbelt Securities Inc. boosted its holdings in GSK by 73.8% in the third quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company’s stock worth $29,000 after acquiring an additional 302 shares in the last quarter. EverSource Wealth Advisors LLC increased its position in GSK by 9.4% during the second quarter. EverSource Wealth Advisors LLC now owns 3,542 shares of the pharmaceutical company’s stock valued at $137,000 after acquiring an additional 303 shares during the last quarter. Mesirow Financial Investment Management Inc. lifted its holdings in GSK by 2.0% in the third quarter. Mesirow Financial Investment Management Inc. now owns 16,693 shares of the pharmaceutical company’s stock valued at $682,000 after acquiring an additional 323 shares during the period. International Assets Investment Management LLC grew its stake in shares of GSK by 6.3% during the 2nd quarter. International Assets Investment Management LLC now owns 5,535 shares of the pharmaceutical company’s stock valued at $213,000 after purchasing an additional 327 shares during the period. Finally, Rehmann Capital Advisory Group increased its position in shares of GSK by 6.3% during the 3rd quarter. Rehmann Capital Advisory Group now owns 5,608 shares of the pharmaceutical company’s stock valued at $232,000 after purchasing an additional 332 shares during the last quarter. 15.74% of the stock is owned by institutional investors.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.